Randomized clinical trial concerning diet for outpatients treated with chemotherapy in Hematology /Clinical Oncology division

Randomized clinical trial concerning diet for outpatients treated with chemotherapy in Hematology /Clinical Oncology division - Diet Trial for Hematological Malignacies

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000020875

Enrollment

440

Registered

2016-02-04

Start date

2015-09-14

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Malignant lymphoma Multiple myeloma Myelodysplastic syndrome Chronic lymphatic leukemia

Interventions

The group of the patients who have diet to be restricted only to heated food up to the end of the first three cycles The group of the patients who can eat anything without any restriction in the first

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The patients who are diagnosed as having malignant lymphoma, multiple myeloma, myelodysplastic syndrome, or chronic lymphocytic lymphoma, who will be treated with chemotherapy as outpatients at least in one cycle among the first three cycles

Exclusion criteria

Exclusion criteria: none

Design outcomes

Primary

Measure	Time frame
The incidence of infection of Grade 3 or more in the first three cycles	—

Secondary

Measure	Time frame
In the first three cycles,thefollowing are to be evaluated as secondary outcoms:1) the incidence of infection of Grade3 ormore with the obvious focus and with neutropenia, 2)the incidence of infection of Grade3 or more without neutropenia, 3) the incidence of febrile neutropenia of Grade3 or more, 4) the rate of discontinuation of treatment due to infection, 5) the rate of postponement of traetment, 6) the difference in the patients' satisfaction between the two diet groups, and 7) the difference in the nutrition state between the two diet groups.	—

Measure

Time frame

In the first three cycles,thefollowing are to be evaluated as secondary outcoms:1) the incidence of infection of Grade3 ormore with the obvious focus and with neutropenia, 2)the incidence of infection of Grade3 or more without neutropenia, 3) the incidence of febrile neutropenia of Grade3 or more, 4) the rate of discontinuation of treatment due to infection, 5) the rate of postponement of traetment, 6) the difference in the patients' satisfaction between the two diet groups, and 7) the difference in the nutrition state between the two diet groups.

—

Countries

Japan

Contacts

Public ContactMami Mizoguchi

Komaki City Hospital Regional Cooperation Division

Renkei@city.komaki.lg.jp0568-76-4131

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026